trial

A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

NCTId NCT01614899
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 457 (actual)
Sponsored by Sumitomo Pharmaceuticals America
Primary completion 2014-11-17
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
457 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2012-07-02
Primary completion
2014-11-17
Eligibility
ALL · 18 Years · 74 Years

Interventions & indications

Drugs
SM-13496 40mgSM-13496 80mg

Sponsors

Sumitomo Pharmaceuticals AmericaLead Sponsor

Investigators

1
Clinical Development Drug development DivisionStudy Director

Sites

4 total
Tokyo, Etc, JapanKuala Lumpur, Etc, MalaysiaSeoul, Etc, South KoreaTaipei, Etc, Taiwan

Linked catalysts

1
A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia — primary completion2014-11-17

Facts & assertions

4 sourced
Enrollment
457
Phase
PHASE3
Primary Completion Date
2014-11-17
Status
COMPLETED
relationships
The graph out of here
drug
SM-13496 40mg
drug
SM-13496 80mg
drug
lead_sponsor
Sumitomo Pharmaceuticals America
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Clinical Development Drug development Division
person